Li Gao

Li Gao

Auto-generated profile, based on publicly available information

Li Gao

Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, The Key Laboratory of Anti-Inflammatory of Immune Medicines, Ministry of Education, School of Pharmacy, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Molecular Therapy
Verified
Journal Article
Open access
LJLing Jiang
Ling Jiang
XLXueqi Liu
Xueqi Liu
XHXueru Hu
Xueru Hu
LGLi Gao
Li Gao
HZHanxu Zeng
Hanxu Zeng
YWYonggui Wu
Yonggui Wu
Epigenetic changes are present in many physiological and pathological processes. The N6-methyladenosine (m6A) modification is the most common modification in eukaryotic mRNA. However, the role of m6A modification in diabetic nephropathy (DN) remains elusive. Here, we found that m6A modification was significantly upregulated in the kidney of type 1 and type 2 diabetic mice, which was caused by elevated levels of METTL3. Moreover, METTL3 is increased in podocyte of renal biopsy from patients with DN, which is related to renal damage. METTL3 knockout significantly reduced the inflammation and apoptosis in high glucose (HG)-stimulated podocytes, while its overexpression significantly aggravated these responses in vitro. Podocyte-conditional knockout METTL3 significantly alleviated podocyte injury and albuminuria in streptozotocin (STZ)-induced diabetic mice. Therapeutically, silencing METTL3 with adeno-associated virus serotype-9 (AAV9)-shMETTL3 in vivo mitigated albuminuria and histopathological injury in STZ-induced diabetic mice and db/db mice. Mechanistically, METTL3 modulated Notch signaling via the m6A modification of TIMP2 in an insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2)-dependent manner and exerted pro-inflammatory and pro-apoptotic effects. In summary, this study suggested that METTL3-mediated m6A modification is an important mechanism of podocyte injury in DN. Targeting m6A through the writer enzyme METTL3 is a potential approach for the treatment of DN.

14 February 2020 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
LGLi Gao
Li Gao
XZXiang Zhong
Xiang Zhong
JJJuan Jin
Juan Jin
JLJun Li
Jun Li
XMXiao-ming Meng
Xiao-ming Meng
Acute kidney injury (AKI) is defined as a rapid decline in renal function and is characterized by excessive renal inflammation and programmed death of resident cells. AKI shows high morbidity and mortality, and severe or repeated AKI can transition to chronic kidney disease (CKD) or even end-stage renal disease (ESRD); however, very few effective and specific therapies are available, except for supportive treatment. Growth factors, such as epidermal growth factor (EGF), insulin-like growth factor (IGF), and transforming growth factor-β (TGF-β), are significantly altered in AKI models and have been suggested to play critical roles in the repair process of AKI because of their roles in cell regeneration and renal repair. In recent years, a series of studies have shown evidence that growth factors, receptors, and downstream effectors may be highly involved in the mechanism of AKI and may function in the early stage of AKI in response to stimuli by regulating inflammation and programmed cell death. Moreover, certain growth factors or correlated proteins act as biomarkers for AKI due to their sensitivity and specificity. Furthermore, growth factors originating from mesenchymal stem cells (MSCs) via paracrine signaling or extracellular vesicles recruit leukocytes or repair intrinsic cells and may participate in AKI repair or the AKI-CKD transition. In addition, growth factor-modified MSCs show superior therapeutic potential compared to that of unmodified controls. In this review, we summarized the current therapeutic and diagnostic strategies targeting growth factors to treat AKI in clinical trials. We also evaluated the possibilities of other growth factor-correlated molecules as therapeutic targets in the treatment of AKI and the AKI-CKD transition.

6 December 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
LGLi Gao
Li Gao
WWWei-Feng Wu
Wei-Feng Wu
LDLei Dong
Lei Dong
GRGui-Ling Ren
Gui-Ling Ren
HLHai-Di Li
Hai-Di Li
XMXiao-ming Meng
Xiao-ming Meng
Cisplatin is a classic chemotherapeutic agent widely used to treat different types of cancers including ovarian, head and neck, testicular and uterine cervical carcinomas. However, cisplatin induces acute kidney injury by directly triggering an excessive inflammatory response, oxidative stress and programmed cell death of renal tubular epithelial cells. All of which lead to higher mortality rates in patients. In this study we examined the protective effect of protocatechuic aldehyde (PA) in vitro in cisplatin-treated tubular epithelial cells and in vivo in cisplatin nephropathy. PA is a monomer of Traditional Chinese Medicine isolated from the root of S. miltiorrhiza. Results show that PA prevented cisplatin-induced decline of renal function and histological damage, which was confirmed by attenuation of KIM1 in both mRNA and protein levels. Moreover, PA reduced renal inflammation by suppressing oxidative stress and programmed cell death in response to cisplatin, which was further evidenced by in vitro data. Of note, PA suppressed NAPDH oxidases, including Nox2 and Nox4, in a dosage-dependent manner. Moreover, silencing Nox4, but not Nox2, removed the inhibitory effect of PA on cisplatin-induced renal injury, indicating that Nox4 may play a pivotal role in mediating the protective effect of PA in cisplatin-induced acute kidney injury. Collectively, our data indicate that PA largely blocked cisplatin-induced acute kidney injury by suppressing Nox-mediated oxidative stress and renal inflammation without compromising anti-tumor activity of cisplatin. These findings suggest that PA and its derivatives may serve as potential protective agents for cancer patients with cisplatin treatment.

17 May 2024 in Phytomedicine
Verified
Journal Article
Closed access
SGShanshan Guo
Shanshan Guo
LZLang Zhou
Lang Zhou
XLXueqi Liu
Xueqi Liu
LGLi Gao
Li Gao
YLYuanyuan Li
Yuanyuan Li
YWYonggui Wu
Yonggui Wu

8 August 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YHYue-Bo Huang
Yue-Bo Huang
LJLing Jiang
Ling Jiang
Xueqi LiuXueqi Liu
Xueqi Liu
XWXian Wang
Xian Wang
LGLi Gao
Li Gao
YWYonggui Wu
Yonggui Wu
Acute kidney injury (AKI) is still a puzzling clinical problem; its pathophysiology is not completely understood. Up to now, an effective treatment for AKI is lacking. Ferroptosis is a novel form of regulated cell death characterized by the lethal accumulation of lipid hydroperoxides that are dependent on iron and reactive oxygen species and mitochondrial dysfunction. Recently, ferroptosis was shown to play a vital role in AKI such as ischemia‐reperfusion kidney injury and folic acid‐induced AKI. Melatonin (MT) is an antioxidant that regulates the sleep‐wake cycle. While the therapeutic effect of melatonin on AKI has been reported, its mechanism for the treatment of renal ferroptosis remains unclear. We found that melatonin treatment significantly alleviated the serum biochemistry index and histopathological alterations in vivo AKI models induced by bilateral renal artery ischemia reperfusion and folic acid in mice. Ferroptosis induced by hypoxia and reoxygenation or erastin (Era) in mouse tubular epithelial cells (MTEC) was also rescued by melatonin treatment. RNA sequence analysis of ferroptosis‐related genes showed that melatonin affects oxidative stress responses by inhibiting hypoxia and reoxygenation‐ (HR‐) mediated downregulation of NRF2 and upregulation of Slc7a11 in MTEC. Specific knockdown of NRF2 increased the sensitivity of cells to ferroptosis, and melatonin failed to protect against ferroptosis in the HR condition. Together, our data indicate that melatonin prevents ferroptosis in AKI by acting on the NRF2/Slc7a11 axis.

26 March 2018 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
LGLi Gao
Li Gao
MLMing-Ming Liu
Ming-Ming Liu
HZHong-Mei Zang
Hong-Mei Zang
QMQiu-Ying Ma
Qiu-Ying Ma
QYQin Yang
Qin Yang
XMXiao-ming Meng
Xiao-ming Meng